• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech

expresspharmaDecember 31, 2020

Tag: SEC , SII , Bharat Biotech

The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) met on December 30, 2020, in the afternoon to consider the Emergency Use Authorisation (EUA) requests of Pfizer, Serum Institute of India (SII) and Bharat Biotech.

Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech were perused and analysed by the SEC.

The analysis of the additional data and information is going on. SEC will convene again on January 1, 2021.

Previous:Recipharm, Moderna sign deal for manufacturing, fill-finish of COVID-19 vaccines

Next:Awaiting India’s approval for COVISHIELD: SII

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol

(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol
(3beta,5Z,7E,10alpha,22E)-9,10-Secoergosta-5,7,22-trien-3-ol

(3beta,5Z,7E,10alpha,22E)-9,10-Secoergosta-5,7,22-trien-3-ol
Biosecurity transport box

Biosecurity transport box
Omeprazole 99%min EP Pharmaceutical API Acid secretion inhibitors made in china

Omeprazole 99%min EP Pharmaceutical API Acid secretion inhibitors made in china
1,3,2 - the second N - oxa - B, 2 - ( 2' - chloro [ 1,1' - biphenyl ]-2- base ) -4,4,5,5 - tetrameth

1,3,2 - the second N - oxa - B, 2 - ( 2' - chloro [ 1,1' - biphenyl ]-2- base ) -4,4,5,5 - tetrameth
sec-butylmagnesium chloride

sec-butylmagnesium chloride
di-sec-butyldisulfide（5943-30-6）

di-sec-butyldisulfide（5943-30-6）
Secondary Antioxidants YD 168

Secondary Antioxidants YD 168
di-sec-butylamine（626-23-3）

di-sec-butylamine（626-23-3）
Sec-butyl mercaptan

Sec-butyl mercaptan

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service